Your browser doesn't support javascript.
loading
SEOM clinical guideline of diagnosis and management of low-grade glioma (2017)
Sepúlveda-Sánchez, JM; Muñoz Langa, J; Arráez, MA; Fuster, J; Hernández Laín, A; Reynés, G; Rodríguez González, V; Vicente, E; Vidal Denis, M; Gallego, Ó.
Affiliation
  • Sepúlveda-Sánchez, JM; Hospital Universitario. Neurooncology Unit. Madrid. Spain
  • Muñoz Langa, J; Hospital Universitari I Politècnic la Fe. Medical Oncology Department. Valencia. Spain
  • Arráez, MA; Hospital Regional Universitario Carlos Haya. Neurosurgery Department. Málaga. Spain
  • Fuster, J; Hospital Universitari Son Espases. Medical Oncology Department. Palma de Mallorca. Spain
  • Hernández Laín, A; Hospital Universitario. Neuropathology Department. Madrid. Spain
  • Reynés, G; Hospital Universitari I Politècnic la Fe. Medical Oncology Department. Valencia. Spain
  • Rodríguez González, V; Hospital Universitario. Radiation Oncology Department. Madrid. Spain
  • Vicente, E; Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria. Medical Oncology Department. Las Palmas. Spain
  • Vidal Denis, M; Hospital Regional Universitario Carlos Haya. Neuroradiology Unit. Málaga. Spain
  • Gallego, Ó; Hospital de la Santa Creu I Sant Pau. Medical Oncology Department. Barcelona. Spain
Clin. transl. oncol. (Print) ; 20(1): 3-15, ene. 2018. tab, ilus
Article in English | IBECS | ID: ibc-170462
Responsible library: ES1.1
Localization: BNCS
ABSTRACT
Diffuse infiltrating low-grade gliomas include oligodendrogliomas and astrocytomas, and account for about 5% of all primary brain tumors. Treatment strategies for these low-grade gliomas in adults have recently changed. The 2016 World Health Organization (WHO) classification has updated the definition of these tumors to include their molecular characterization, including the presence of isocitrate dehydrogenase (IDH) mutation and 1p/19p codeletion. In this new classification, the histologic subtype of grade II-mixed oligoastrocytoma has also been eliminated. The precise optimal management of patients with low-grade glioma after resection remains to be determined. The risk-benefit ratio of adjuvant treatment must be weighed for each individual (AU)
RESUMEN
No disponible
Subject(s)
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: Available Collection: National databases / Spain Health context: SDG3 - Target 3.8 Achieve universal access to health / SDG3 - Health and Well-Being Health problem: Delivery Arrangements / Target 3.8 Achieve universal access to health Database: IBECS Main subject: Glioma / Neoplasm Staging Type of study: Diagnostic study / Practice guideline Limits: Humans Language: English Journal: Clin. transl. oncol. (Print) Year: 2018 Document type: Article Institution/Affiliation country: Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria/Spain / Hospital Regional Universitario Carlos Haya/Spain / Hospital Universitari I Politècnic la Fe/Spain / Hospital Universitari Son Espases/Spain / Hospital Universitario/Spain / Hospital de la Santa Creu I Sant Pau/Spain
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: Available Collection: National databases / Spain Health context: SDG3 - Target 3.8 Achieve universal access to health / SDG3 - Health and Well-Being Health problem: Delivery Arrangements / Target 3.8 Achieve universal access to health Database: IBECS Main subject: Glioma / Neoplasm Staging Type of study: Diagnostic study / Practice guideline Limits: Humans Language: English Journal: Clin. transl. oncol. (Print) Year: 2018 Document type: Article Institution/Affiliation country: Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria/Spain / Hospital Regional Universitario Carlos Haya/Spain / Hospital Universitari I Politècnic la Fe/Spain / Hospital Universitari Son Espases/Spain / Hospital Universitario/Spain / Hospital de la Santa Creu I Sant Pau/Spain